ACRO Biomedical Co Azione

ACRO Biomedical Co EBITDA

Il EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di ACRO Biomedical Co (ACBM) al 14 ago 2026 è -154.000,00 USD. L'anno precedente, EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) era -38.000,00 USD — una variazione del 305,26% (inferiore).

EBITDA

-154.000,00USD

YoY

305,26%

Ultimo aggiornamento:

EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di ACRO Biomedical Co ammonta a 2026 -154.000,00 USD. EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di ACRO Biomedical Co ammontava a 2025 -38.000,00 USD. Diminuisce del 305,26% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

ACRO Biomedical Co Analisi delle Azioni

Cosa fa ACRO Biomedical Co? ACRO Biomedical Co Ltd is a leading company in biomedical technology based in Taipei, Taiwan. The company was established in 2006 and has since successfully established itself in the global market for biomedical products and technologies. The company's vision is to improve people's lives and promote health worldwide through innovative and high-quality products and solutions. Business model: ACRO Biomedical Co Ltd specializes in the development, manufacturing, and marketing of biomedical products and technologies. The company has three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology. Each division focuses on developing products and solutions tailored to the needs of patients and medical professionals. Regenerative Medicine: ACRO Biomedical Co Ltd is a leading provider of regenerative biomedical products. Under this division, the company develops innovative solutions for tissue regeneration, such as bioimplants made from natural tissues and biomaterials to repair or restore damaged tissue. These products are used for the treatment of injuries, chronic diseases, and degenerative conditions. Additionally, ACRO Biomedical Co Ltd has also developed solutions for cosmetic and aesthetic applications. Wound Care: ACRO Biomedical Co Ltd's wound care division specializes in developing products and solutions that help accelerate wound healing, prevent infections, and reduce the risk of complications. The company offers a wide range of products, including antimicrobial and moist wound dressings, which are used for the treatment of acute and chronic wounds such as burns, abrasions, and diabetic foot ulcers. Surgical Technology: ACRO Biomedical Co Ltd's surgical technology division provides healthcare professionals with a wide range of surgical products for various applications, including neurosurgery, plastic surgery, and general surgery. The innovative products offered by ACRO Biomedical Co Ltd for surgical applications include cutting tools, implants, and instruments for minimally invasive procedures. Products: ACRO Biomedical Co Ltd offers a wide range of products for various applications and medical specialties. Some of the company's key products include: - ACL-Bioimplant: A bioimplant for cruciate ligament repair made from human cartilage and biomaterials. - ACRO-CAF: A bone grafting material for bone transplantation. - ACRO-Mixtop: A wound healing agent for the treatment of burns, abrasions, and chronic wounds. - ACRO-OSTEOT: A surgical bone drill for orthopedics and neurosurgery. - ACRO-BioSIS: A tissue adhesive for surgical applications. Summary: ACRO Biomedical Co Ltd is a leading company in biomedical technology that offers innovative solutions for the preservation and restoration of people's health. With its three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology, the company provides a wide range of products and solutions for medical professionals and patients. The company's products are marketed worldwide and are known for their quality, reliability, and effectiveness. ACRO Biomedical Co è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su ACRO Biomedical Co azioni

EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di ACRO Biomedical Co è -154.000,00 USD nel 2026.

Il EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) di ACRO Biomedical Co è passato da -38.000,00 USD a -154.000,00 USD, con una variazione del 305,26 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del ACRO Biomedical Co di EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) dal 2006, con valori annuali, grafici e analisi dettagliate.

L'EBITDA misura la performance operativa prima dell'impatto della struttura finanziaria, dell'ambiente fiscale e degli oneri di ammortamento non monetari.

EBITDA = EBIT + Ammortamenti e svalutazioni

Il USD di EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il ACRO Biomedical Co di EBITDA (Guadagni prima di interessi, tasse, ammortamenti e svalutazioni) storicamente e in tempo reale.

Access this data via the Eulerpool API

Conto economico — ACRO Biomedical Co

Tutte le Metriche Finanziarie — ACRO Biomedical Co